Pain Therapeutics Reports Q1 2014 Financial Results

AUSTIN, Texas, May 6, 2014 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for Q1 2014. Net loss in Q1 2014 was $3.5 million, or $0.08 per share, compared to a net loss in Q1 2013 of $0.4 million, or $0.01 per share. Net cash used in Q1 2014 was $2.7 million. At March 31, 2014, cash and investments were $47.1 million. As previously disclosed, the Company believes net cash usage for 2014 may be approximately $12 million.

"We continue to carefully monitor the progress of REMOXY by Pfizer," said Remi Barbier, President & CEO. "We also continue to believe the next few quarters ahead may be pivotal for the Company and its shareholders."

Financial Highlights for Q1 2014               
  • At March 31, 2014, cash and investments were $47.1 million, compared to $49.8 million at December 31, 2013. We have no debt.  
  • Net cash used in Q1 2014 was $2.7 million.  
  • Research and development expenses increased to $2.1 million in Q1 2014 from $1.2 million in Q1 2013, primarily due to increased investment in early stage drug assets. Research and development expenses included non-cash stock-related compensation costs of $0.3 million in Q1 of both 2014 and 2013.  
  • General and administrative expenses increased slightly to $1.3 million in Q1 2014 from $1.2 million in Q1 2013, primarily due to increased non-cash stock-related compensation. General and administrative expenses included non-cash stock-related compensation costs of $435,000 in Q1 2014 and $376,000 in Q1 2013.

ABOUT REMOXY ®

Our lead drug candidate, REMOXY (oxycodone) Extended-Release Capsules CII, is an oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage common methods of tampering and misuse. Pfizer, Inc. (NYSE:PFE) is our exclusive, worldwide commercial partner for REMOXY, except as to Australia and New Zealand.

If you liked this article you might like

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Pfizer (PFE) Stock Falls After Dropping Pain Drug

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan